SCHEMBL17942791

SCHEMBL17942791

Nc1cccc2oc3cc(F)ccc3c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 5/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NQO1 P15559 2/20 0.37
▸ CDC25A P30304 1/20 0.37
▸ CDC25C P30307 1/20 0.37
▸ ESR1 P03372 2/20 0.36
▸ ESR2 Q92731 2/20 0.36
▸ CYP11B1 P15538 2/20 0.35
▸ CYP11B2 P19099 2/20 0.35
▸ MGAM O43451 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SI P14410 1/20 0.35
▸ MGAM2 Q2M2H8 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17942574 0.86 GABRP (0.43) ALDH1A1KDM4EMEN1MAPTHPGD
SCHEMBL23105530 0.81 ALDH1A1 (0.61) ALDH1A1KDM4EMEN1MAPTHPGD
SCHEMBL24725891 0.79 MAPT (0.41) MAOBALDH1A1KDM4EMEN1MAPT
SCHEMBL24726918 0.79 PARP1 (0.45) MAOBMEN1HPGDKMT2ANQO1
SCHEMBL21638102 0.79 TTR (0.47) MAOBMEN1KMT2ANQO1CDC25A
SCHEMBL23105436 0.79 ALDH1A1 (0.41) MAOBALDH1A1KDM4EMEN1MAPT
SCHEMBL31248014 0.79 MAOB (0.41) MAOBALDH1A1KDM4EMEN1MAPT
SCHEMBL2337790 0.77 ALDH1A1 (0.50) ALDH1A1KDM4EMEN1MAPTHPGD
SCHEMBL22450150 0.76 KDM4E (0.42) ALDH1A1KDM4EMEN1MAPTHPGD
Iodide SCHEMBL8114884 0.75 ALDH1A1 (0.48) ALDH1A1KDM4EMEN1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3247692-B1 INHIBITORS OF TRKA KINASE GVK BIOSCIENCES PRIVATE LTD (IN) 2022-09-07 — — EP disclosed
US-10336723-B2 Inhibitors of TrkA kinase GVK BIOSCIENCES PRIVATE LIMITED (IN) 2019-07-02 — — US disclosed
US-20180009781-A1 INHIBITORS OF TRKA KINASE GVK BIOSCIENCES PRIVATE LIMITED (IN) 2018-01-11 — — US disclosed
EP-3247692-A1 INHIBITORS OF TRKA KINASE GVK Biosciences Private Limited (IN) 2017-11-29 — — EP disclosed
WO-2016116900-A1 INHIBITORS OF TRKA KINASE GVK BIOSCIENCES PRIVATE LIMITED (IN) 2016-07-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009781-A1 INHIBITORS OF TRKA KINASE NGFR, NGF, NTRK1 MAOB 2030/4885ALDH1A1 2186/4885KDM4E 2967/4885
US-10336723-B2 Inhibitors of TrkA kinase NGFR, EDNRA, NGF MAOB 1481/4885ALDH1A1 2317/4885KDM4E 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback